NASDAQ:EQRX - EQRx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.80
  • Forecasted Upside: 29.03 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.27
+0 (0.00%)

This chart shows the closing price for EQRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New EQRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EQRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EQRX

Analyst Price Target is $6.80
▲ +29.03% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for EQRx in the last 3 months. The average price target is $6.80, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 29.03% upside from the last price of $5.27.

This chart shows the closing price for EQRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in EQRx.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/13/2022The Goldman Sachs GroupInitiated CoverageBuy$8.00High
4/22/2022CowenInitiated CoverageOutperformHigh
4/22/2022CowenInitiated CoverageOutperformHigh
3/18/2022Jefferies Financial GroupInitiated CoverageBuy$5.60High
(Data available from 7/7/2017 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/7/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
7/7/2022

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
EQRx logo
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.27
Low: $5.05
High: $5.33

50 Day Range

MA: $4.60
Low: $3.20
High: $5.69

52 Week Range

Now: $5.27
Low: $2.63
High: $10.49

Volume

2,922,341 shs

Average Volume

3,562,291 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of EQRx?

The following Wall Street sell-side analysts have issued stock ratings on EQRx in the last year: Cowen Inc, Cowen Inc., Jefferies Financial Group Inc., and The Goldman Sachs Group, Inc..
View the latest analyst ratings for EQRX.

What is the current price target for EQRx?

0 Wall Street analysts have set twelve-month price targets for EQRx in the last year. Their average twelve-month price target is $6.80, suggesting a possible upside of 29.0%.
View the latest price targets for EQRX.

What is the current consensus analyst rating for EQRx?

EQRx currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EQRX will outperform the market and that investors should add to their positions of EQRx.
View the latest ratings for EQRX.

How do I contact EQRx's investor relations team?

EQRx's physical mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The company's listed phone number is 212-474-6745 and its investor relations email address is [email protected] The official website for EQRx is iii.cmlifesciencesspac.com. Learn More about contacing EQRx investor relations.